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ABSTRACT
Esophageal adenocarcinoma (EAC) is typically diagnosed in elderly with a median 
age of 68 years. The incidence of EAC has been rising over the last decades, also 
among young adults. The aim of the study was to investigate whether early onset 
EAC is a distinct molecular entity. 
To identify early onset EACs, the nationwide network and registry of histo- and 
cytopathology in the Netherlands (PALGA) was searched. Twenty-eight tumors of 
patients aged ≤40 years were selected and matched with 27 tumors of patients aged 
≥68 years. DNA was isolated from surgically resected specimen and sequenced on the 
Ion Torrent Personal Genome Machine with the Ion AmpliSeq Cancer Panel. 
No differences in mutational load between early onset and conventional EACs 
were observed (P=0.196). The most frequently mutated genes were TP53 (73%) and 
P16 (16%). Additional mutations in early onset EACs occurred exclusively in: APC, 
CDH1, CTNNB1, FGFR2, and STK11. In the conventional EACs additional mutations 
were exclusively identified in: ABL1, FBXW7, GNA11, GNAS, KRAS, MET, SMAD4, and 
VHL.
Additional mutations besides TP53 and P16 seem to occur in different genes 
related to cell fate pathways for early onset EACs, while the additional mutations in 
conventional EACs are related to survival pathways. 
INTRODUCTION
Esophageal adenocarcinoma (EAC) is typically 
diagnosed in elderly adults with a median age of 68 
years [1]. The incidence of EAC has been rising rapidly 
over the last decades, also among young adults [2, 3]. 
The clinicopathological characteristics of these young 
adults with early onset EACs are different compared to 
the conventional EAC of the older patients: those with 
early onset EAC suffer from less co-morbidities, present 
with advanced disease stages more often, undergo more 
aggressive treatments, but ultimately obtain the same 
relative five-year survival rates as their older counterparts 
[4-6]. Individuals can be predisposed to early onset EAC 
through heredity, since seven percent of the patients 
diagnosed with EAC can be considered Familial Barrett’s 
Esophagus (FBE), of which the age at diagnosis is 
generally lower compared to sporadic cases [7, 8], yet 
no genetic defects related to FBE have been identified. 
Nevertheless, early onset EAC can be sporadic as well, 
lacking a genetic predisposition. 
It has been accepted that cancer is generally a 
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disease of the elderly population. In addition, evidence 
is obtained that the transformation of a normal cell into 
a malignant cell and subsequently the outgrowth to a 
clinically manifest lesion takes several decades [9]. This 
transformation process is driven by genomic instability 
leading to the accumulation of mutations. About three 
mutations in driver genes, which are causally involved 
in the tumorigenic process, have to accumulate to induce 
this malignant transformation [10]. As a result of the 
genomic instability also passenger mutations, which are 
not involved in the tumorigenic process, will accumulate. 
Hence, it can be anticipated that early onset EACs went 
through an accelerated transformation process and as a 
result could have a lower mutational load of (passenger) 
mutations, as has been reported for other tumors before 
[11]. In addition, it is possible that early onset EAC is a 
distinct molecular entity as has been demonstrated e.g. for 
colorectal carcinoma [12]. 
The aim of the present study was to investigate 
whether early onset EAC is a distinct molecular entity. 
By next-generation sequencing with a standard cancer 
panel the mutational load and molecular profile of early 
onset EACs was determined and compared with the 
conventional EACs. 
RESULTS
Thirty-seven patients diagnosed with EAC or 
adenocarcinoma of the gastro-esophageal junction (GEJ) 
and aged ≤40 years at time of diagnosis were identified 
in the PALGA database. Twenty-eight samples obtained 
from these patients passed quality controls and were 
included in the study (mean age: 37.2 years, range 28-40 
years, 89% male). Twenty-seven patients diagnosed with 
EAC or adenocarcinoma of the GEJ and aged ≥68 years 
at time of diagnosis were matched with patients aged ≤40 
years based on TNM-stage and tumor differentiation grade 
(Mean age: 74.6 years, range 68-83 years, 78% male). All 
tumors were tested microsatellite stable. Of the patients 
aged ≤40 years seven received some form of neoadjuvant 
therapy, while none of the patients aged ≥68 years did. 
Patients- and tumor characteristics are listed in Table 1 
according to age groups.
Next-Generation sequencing with the Ion Torrent 
Personal Genome Machine (PGM) revealed 83 mutations 
in 55 EAC samples before filtering: 36 mutations in the 
patients aged ≤40 years and 47 mutations in the patients 
aged ≥68 years (P = 0.094). After filtering 78 mutations 
remained: 35 mutations were identified in the patients 
Table 1: Patient- and tumor characteristics according to age groups
Early onset EAC
n = 28 (%)
Conventional EAC
n = 27 (%) p-value (χ2)
Mean Age (sd) 37.21(3.023) 74.63 (4.395) <0.001 (T-test)
Gender
Male
Female
25 (89.3)
3 (10.7)
21 (77.8)
6 (22.2)
0.249
Tumor type
EAC
GEJAC
Cardia
Unknown
16 (57.1)
9 (32.1)
2 (7.1)
1 (3.6) 
17 (63.0)
9 (33.3)
1 (3.7)
0 (0)
0.718
TNM stage*
IA 
IB
IIA
IIB
IIIA
IIIB
IIIC
IV
5 (17.9)
3 (10.7)
0 (0)
2 (7.1)
9 (32.1)
3 (10.7)
5 (17.9)
1 (3.6)
3 (11.1)
0 (0)
1 (3.7)
7 (25.9)
7 (25.9)
2 (7.4)
6 (22.2)
1 (3.7)
0.350
Differentiation grade
High grade dysplasia
Good
Moderate
Poor
Unknown
0 (3.6)
4 (14.3) 
11 (39.3)
9 (32.1)
4 (14.3) 
0 (0)
0 (0)
16 (59.3)
9 (33.3)
2 (7.4)
0.233
EAC= esophageal adenocarcinoma
GEJAC= gastro-esophageal junction adenocarcinoma
*According to the classification of the American Joint Committee on Cancer (AJCC) Staging 
Manual 7th edition.
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aged ≤40 years and 43 mutations in the patients aged ≥68 
years. The mean number of mutations for the young adults 
and the older patients was, 1.25 (SD 0.844) and 1.59 (SD 
1.083) respectively, and not significantly different (P = 
0.196). 
The most frequently mutated genes were TP53 
(73%), P16 (16%), ATM (7%), and RB1 (7%). In the 
early onset EACs TP53 was altered in 75% and P16 in 
11%, whereas in the conventional EACs a mutation in 
TP53 was found in 70% and P16 was mutated in 22%. 
Except for one, all P16 mutations occurred simultaneously 
with a TP53 mutation. In 43% of the early onset EACs 
and in 33% of the conventional EACs no additional 
mutations besides a TP53 mutations or a P16 mutations 
were identified. The genes ATM, JAK3, PIK3CA, and RB1 
were mutated equally between both groups. Additional 
mutations in five individual early onset EACs occurred 
exclusively in the genes: APC, CDH1, CTNNB1, FGFR2, 
and STK11. In the conventional EACs additional mutations 
were exclusively identified in the genes: ABL1, FBXW7, 
GNA11, GNAS, KRAS, MET, SMAD4, and VHL (Figure 1 
and Table 2).
DISCUSSION
For the first time a molecular analysis was performed 
on an exclusive group of patients with early onset EACs, 
to determine whether this is a distinct entity based on 
molecular spectrum. In comparison with the conventional 
EACs no difference in the total mutational load, including 
common driver mutations, was observed in the early onset 
EACs. Although no evidently differences were observed 
between the two groups with regard to molecular profile, 
the additional mutations, besides mutations in TP53 and 
P16, identified in some individual early onset EACs 
differed when compared to the additional mutations 
identified in the conventional EACs. 
Presently, there is no accepted clear definition of 
early onset EACs. Recent publications demonstrate that 
5% of the patients diagnosed with EAC are aged ≤40 years 
[5] and 10% aged ≤ 50 years [6]. In these studies young 
adults with EAC were compared with the conventional 
EAC patients, with a median age of 68 years, based on 
clinicopathological characteristics, showing that these 
younger patients present with more advanced disease 
stages, receive more often aggressive treatment regimes, 
however, ultimately obtain relative survival rates 
comparable with their older counterparts [6]. In order to 
ensure a clear segregation of the two entities and to avoid 
any overlap, a more restrictive definition of both early 
onset EAC and conventional EAC was used and patients 
between 41 and 67 years were excluded in the present 
study.
EAC evolves from the premalignant condition 
Barrett’s esophagus, following a multimorphological 
pathway, in which metaplasia evolves to low-grade 
dysplasia, high-grade dysplasia and ultimately into 
invasive adenocarcinoma, during this malignant 
transformation mutations accumulate over time [9, 13]. 
The number of mutations in a tumor originating from 
self-renewing tissue, e.g. the esophagus, is directly 
correlated with age. The majority of these mutations are 
passenger mutations that have no effect on the neoplastic 
progression. Whereas, the minority are the driver 
mutations, which confer a selective growth advantage. 
The passenger mutations occur mostly during the pre-
neoplastic phase, which is evidently longer for older 
patients than for the younger ones [14]. Based on this 
concept it can be hypothesized that the number of total 
mutations, i.e. mutational load, is lower in early onset 
Figure 1: Mutations identified in early onset EACs and conventional EACs classified to cell signaling pathways.
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EACs as compared to conventional EACs. 
Although it did not reached the level of significance, 
probably due to the relatively small amount of patients, 
a higher amount of total mutations (i.e. passenger and 
driver mutations) was observed in the conventional 
EACs when compared to the early onset EACs, which 
is in line with concept as has been described previously. 
The current data did not revealed a significant difference 
in the load of driver mutations between the two age 
groups. Since the use of the Cancer Hotspot panel in 
this study, by which only 207 gene “hot spot” regions 
are investigated that are frequently mutated in human 
cancers, not all genes were covered. Hence, a complete 
overview of the total mutation spectrum per patient could 
not be established. An alternative explanation for the 
comparable load of mutations between the early onset 
Table 2: Extensive information of classification of genes in signaling pathways and cellular processes according to age 
groups.
Gene Gene Name Early onset/Conventional Classification
Core 
pathway
Cellular 
process
ABL1 C-abl oncogene 1, non-receptor tyrosine kinase Conventional Oncogene
Cell Cycle/
Apoptosis Cell Survival
APC Adenomatous polyposis coli Early onset Tumor suppressor gene APC Cell Fate
ATM Ataxia telangiectasia mutated Early onset/Conventional Tumor suppressor gene
DNA 
Damage 
Control
Genome 
Maintenance
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) Early onset Tumor suppressor gene APC Cell Fate
CTNNB1 Catenin (cadherin-associated protein), beta 1, 88kDa Early onset Oncogene APC Cell Fate
FBXW7 F-box and WD repeat domain containing 7 Conventional Tumor suppressor gene NOTCH Cell Fate
FGFR2 Fibroblast growth factor receptor 2 Early onset Oncogene PI3K; RAS ; STAT Cell Survival
GNA11 Guanine nucleotide binding protein (G protein), alpha 11 (Gq class) Conventional Oncogene
PI3K; 
RAS; 
MAPK
Cell Survival
GNAS GNAS complex locus Conventional Oncogene
APC; 
PI3K; 
TGF-β, 
RAS
Cell Survival/
Cell Fate
JAK3 Janus kinase 3 Early onset/Conventional Oncogene STAT Cell Survival
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog Conventional Oncogene RAS Cell Survival
MET Met proto-oncogene (hepatocyte growth factor receptor) Conventional Oncogene PI3K; RAS Cell Survival
P16 Cyclin-dependent kinase inhibitor 2A Early onset/Conventional Tumor suppressor gene
Cell Cycle/
Apoptosis Cell Survival
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, catalytic subunit alpha
Early onset/
Conventional Oncogene PI3K Cell Survival
RB1 Retinoblastoma 1 Early onset/Conventional Tumor suppressor gene
Cell Cycle/
Apoptosis Cell Survival
SMAD4 SMAD family member 4 Conventional Tumor suppressor gene TGF-β Cell Survival
STK11 Serine/threonine kinase 11 Early onset Tumor suppressor gene mTOR Cell Survival
TP53 Tumor protein p53 Early onset/Conventional Tumor suppressor gene
Cell Cycle/
Apoptosis; 
DNA 
Damage 
Control
Genome 
Maintenance
VHL Von Hippel-Lindau tumor suppressor Conventional Tumor suppressor gene
PI3K; 
RAS; 
STAT
Cell Survival
Adapted from Vogelstein et al. 2013 [9]
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EACs and the conventional EACs can be the occurrence 
of an ultramutator phenotype in the young adults 
resulting in an accelerated accumulation of mutations. 
By this phenomenon, young adults with early onset EAC 
could bear a comparable mutational load as compared 
to their older counterparts despite their shorter time of 
tumorigenesis [15]. 
At a first glance no evidently differences were 
observed between the early onset EACs and the 
conventional EACs, with regard to the molecular 
profiles: the tumor suppressor gene TP53 was altered in 
approximately 72% of EACs (75% in early onset vs. 70% 
in conventional EACs), which is comparable with other 
studies [16]. Mutations of TP53 have been suggested to be 
an early genetic event in the multimorphological pathway 
of esophageal adenocarcinogenesis and are facilitating 
the accumulation of mutations [9, 17]. Alterations of 
tumor suppressor gene P16 are additional early events 
in EAC, and present in approximately 12% [16]. Here, 
in 11% of the early onset EACs a P16 mutation was 
identified, whereas in the conventional EACs a P16 
mutation was identified in 22%. A remarkable observation 
was made regarding the additional mutational spectrum; 
the genes APC, CDH1, CTNNB1, FGFR2, and STK11 
were exclusively mutated in five individual early onset 
EACs. Whereas these mutations were not identified 
in the conventional EACs, that instead, exclusively 
carried additional mutations in the genes ABL1, FBXW7, 
GNA11, GNAS, KRAS, MET, SMAD4, and VHL. Since 
the additional mutations were identified in five individual 
early onset EACs it might be based on randomness. In 
addition, in a large whole exome sequencing study on 
EACs performed by Dulak et al. mutations in APC, 
CDH1, CTNNB1, FGFR2, and STK11 were identified in 
EAC patients, here categorized as conventional EAC of 
older patients (range: 51-85 years), although in very small 
amounts [16]. 
However, considering the classification of cancer 
cell signaling pathways i.e. cell fate, cell survival, and 
genome maintenance, it is striking that the additional 
mutations in the early onset EACs occurred mainly in 
genes classified in cell fate pathways (APC, CDH1, 
CTNNB1), while all additional mutations in conventional 
EACs were identified in genes classified in survival 
pathways (ABL1, GNA11, KRAS, MET, SMAD4, VHL, 
GNAS, FBXW7). In addition, the shared mutations 
occurred in genes classified in genome maintenance 
pathways (TP53, ATM) as well as in survival pathways 
(JAK3, PIK3CA, P16). Mutations classified in cell fate 
pathways disturb the balance between differentiation 
and division, favoring the latter, which causes a selective 
growth advantage. Mutations categorized in cell 
survival pathways allow cancer cells to proliferate under 
limiting nutrient concentrations, making them survive in 
environments in which sister cells cannot [9]. Different 
biological pathways for patients with early onset cancers 
have been described earlier, for example in breast cancer, 
colorectal cancer, melanoma, and tongue cancer [18].
Taken together, these findings indicate that the 
development of EAC requires, regardless of the age of 
onset, a TP53 mutation mostly accompanied by a P16 
mutation. However, the additional mutations needed 
to probably induce the malignant transformation [10] 
in some early onset EACs seem to occur in different 
genes, related to different pathways, as compared to the 
additional mutated genes in conventional EACs. From a 
treatment perspective, different pathways could indicate 
different inhibitors in the means of targeting treatment as 
has been established for metastatic colorectal cancer [19]. 
The current study gives a clue for a distinct molecular 
biology for early onset EAC. More extensive sequencing 
of larger cohorts of young adults and older patients with 
EAC have to be performed to determine whether early 
onset EAC is truly a distinct molecular entity that needs 
probably a different targeting therapy in the future. 
MATERIALS AND METHODS
Patient identification
PALGA, the nationwide network and registry of 
histopathology and cytopathology, contains pathology 
reports generated in the Netherlands since 1971 and has 
complete national coverage since 1991 encompassing the 
pathology laboratories from all academic and nonacademic 
hospitals in the Netherlands [20]. The PALGA database 
was searched, with approval of their Privacy Commission 
and Scientific Council, to identify all patients diagnosed 
with an adenocarcinoma of the esophagus or the GEJ and 
aged ≤40 years in the Netherlands. The following search 
terms were used: “primary carcinoma,” “esophagus”, 
“stomach,” and “age ≤40 years”. The search was 
performed from January 1990 to March 2013. Cases were 
further confirmed or excluded after careful evaluation of 
the individual pathology reports.
The selected early onset EACs were compared 
with a group of conventional EACs collected from the 
Pathology archive of the Erasmus MC Cancer Institute, 
University Medical Center, Rotterdam. Patients aged 
≥68 years and diagnosed with an adenocarcinoma of 
the esophagus or GEJ for which an esophagectomy 
was performed were selected and matched with the 
patients with early onset EAC with regard to grade of 
tumor differentiation and TNM-stage (according to the 
classification of the American Joint Committee on Cancer 
(AJCC) Staging Manual 7th edition) [21].
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Tissue samples
Formalin fixed paraffin embedded (FFPE) tumor 
tissues were provided by the participating laboratories of 
PALGA. The tissue blocks were assessed anonymously 
according to the Proper Secondary Use of Human Tissue 
code established by the Dutch Federation of Medical 
Scientific Societies (http://www.federa.org). In addition 
the study was approved by The Medical Ethical Committee 
of the Erasmus MC Cancer institute, University Medical 
Center, Rotterdam.
Tumor tissue areas composed of at least 50% 
neoplastic cells (indicated by a GI-pathologist) were 
manually microdissected from 10 to 15 hematoxylin-
stained sections (4µm) of FFPE tissue blocks. DNA was 
extracted using proteinase K and 5% Chelex 100 resin. 
To determine the presence of microsatellite instability 
analyses were performed with the MSI Analysis System, 
Version 1.2 (Promega, Madison, WI, USA). 
Next-generation sequencing
Ion semiconductor sequencing on the PGM was 
performed with the Ion AmpliSeq Cancer Hotspot Panel 
on tumor DNA according to the manufacturer’s protocols. 
In short, libraries were made using the Ion AmpliSeq 
Library Preparation Kit. A template was prepared using 
the Ion OneTouch Template Kit and sequencing was 
performed with the Ion Sequencing Kit v2.0 on an Ion 
316 chip. Data were analyzed with the Variant Caller 
v2.2.3-31149 (Life Technologies, Carlsbad, CA, USA). 
Variants were called when the position was covered at 
least 100 times. Variants found in at least 25% of the 
called reads were considered reliable. Variants present in 
the ESP6500si or 1000genomes databases in ≥1% were 
excluded. Subsequently nonsynonymous somatic point 
mutations, insertions and deletions that change the protein 
amino acid sequence and splice site alterations were 
selected as driver mutations.
Data analysis
Early onset EAC was defined as patients diagnosed 
with EAC at the aged ≤40 years. This group was compared 
with the group of patients aged ≥68 years. Patient- and 
tumor characteristics were described using frequencies 
and percentages. Proportions were compared using χ2 test 
for categorical variables. Differences in the mean number 
of mutations between the age groups were tested using 
independent samples T-test. Two-sided P-values < 0.05 
were considered statistically significant for all analyses. 
Data analysis was performed with SPSS version 20.0 
(SPSS, Chicago, IL, USA).
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